Immuneering
Price & Volume
Stats
See more52W Range | $1.10-$10.08 |
Market Cap | $320.6M |
Shares Short | 11M |
Financials
See moreRevenue (12 Mos) | $455 |
Revenue Growth (YoY) | -99.8% |
Gross Profit (12 Mos) | $158,830 |
Diluted EPS | -$1.27 |
News
See moreYahoo Finance • 14 days ago
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
Yahoo Finance • 3 months ago
Immuneering Prepares To Share 12-Month Survival Data In Pancreatic Cancer Trial
Yahoo Finance • 3 months ago
Immuneering To Initiate Phase 3 Atebimetinib Trial In Pancreatic Cancer In Mid-2026
Yahoo Finance • 3 months ago
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
About
CEO | Dr. Benjamin J. Zeskind M.B.A., Ph.D. |
Address | 245 Main Street, Cambridge, MA, United States, 02142 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 53 |
